<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">TURNER, MICHAEL A.</style></author><author><style face="normal" font="default" size="100%">HOLLANDSWORTH, HANNAH M.</style></author><author><style face="normal" font="default" size="100%">NISHINO, HIROTO</style></author><author><style face="normal" font="default" size="100%">AMIRFAKHRI, SIAMAK</style></author><author><style face="normal" font="default" size="100%">LWIN, THINZAR M.</style></author><author><style face="normal" font="default" size="100%">LOWY, ANDREW M.</style></author><author><style face="normal" font="default" size="100%">KAUR, SUKHWINDER</style></author><author><style face="normal" font="default" size="100%">NATARAJAN, GOPALAKRISHNAN</style></author><author><style face="normal" font="default" size="100%">MALLYA, KAVITA</style></author><author><style face="normal" font="default" size="100%">HOFFMAN, ROBERT M.</style></author><author><style face="normal" font="default" size="100%">BATRA, SURINDER K.</style></author><author><style face="normal" font="default" size="100%">BOUVET, MICHAEL</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">57-62</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.12676</style></doi><volume><style face="normal" font="default" size="100%">36</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">Background: Overexpression of mucin-5AC (MUC5AC) makes it a targetable biomarker in pancreatic cancer. The present study evaluated tumor targeting with a MUC5AC antibody conjugated to a near-infrared dye in a patient-derived orthotopic xenograft (PDOX) mouse model. Materials and Methods: MUC5AC monoclonal antibody was conjugated to the near-infrared dye IRDye800CW to synthesize MUC5AC-IR800. PDOX models were established by implanting a high-MUC5AC-expressing patient-derived pancreatic tumor on the pancreas of nude mice. After 4 weeks of PDOX tumor growth, mice were imaged after receiving MUC5AC-IR800 (75 μg) intravenously. Results: In the PDOX models, MUC5AC-IR800 selectively and brightly targeted the pancreatic tumor (tumor to background ratio: 2.46±0.465). Conclusion: MUC5AC-IR800 provides distinct visualization of pancreatic tumors. MUC5AC-IR800 may be used clinically in the future to improve pancreatic cancer resection. This novel fluorescent probe is also promising for targeting of pre-malignant pancreatic lesions with subsequent resection under fluorescence guidance.</style></abstract></record></records></xml>